Drugs / MB-CART19.1
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07137494 | Aug 2025 → Aug 2028 expected | primary central nervous system lymphoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03853616 | Nov 2018 → Jun 2026 overdue | B-cell chronic lymphocytic leukemia | Miltenyi Biomedicine GmbH | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06189157 | Aug 2024 → Sep 2027 expected | systemic lupus erythematosus | Miltenyi Biomedicine GmbH | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03321123 | Dec 2017 → Jul 2019 | B-cell acute lymphoblastic leukemia | Shanghai Children's Medical Center | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07371403 | Feb 2026 → Jan 2029 expected | B-cell acute lymphoblastic leukemia | King Hussein Cancer Center | Recruiting | No outcome recorded |
| — | NCT06508775 | May 2024 → Dec 2040 expected | childhood acute lymphoblastic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, melanoma | Miltenyi Biomedicine GmbH | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB-CART19.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03853616 ↗ |
| Modality | Cell therapy | “autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells” NCT03853616 ↗ |
| Target | CD19 | “targeting CD19-positive tumor cells” NCT03853616 ↗ |